1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ImmunityBio, Inc.

ImmunityBio, Inc.

IBRX
ImmunityBio, Inc.US flagNASDAQ Global Select
7.32
USD
+0.10
- -
7.67BMarket Cap
ImmunityBio, Inc.
IBRX
(NASDAQ Global Select)

Recent

price

7.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
- -
- -
- -
- -
0.02
0.12
0.15
Revenue per Share
-0.41
-0.58
-0.89
-1.04
-1.15
-0.59
-0.38
-0.89
Basic EPS, GAAP
-0.41
-0.45
-0.79
-1.09
-0.78
-0.57
-0.34
-0.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-4.21
-5.04
-5.95
-5.82
-4.84
-4.05
-4.53
Book Value per Share
- -
-0.31
-0.63
-1.17
-1.19
-0.72
-0.56
-0.92
Tangible Book Value per Share
383
383
389
400
509
697
920
963
Basic Weighted Avg Shares
2
1
1
- -
1
15
113
141
Sales/Revenue/Turnover
-7,095.87
-34,747.11
-35,361.88
-146,090.42
-58,097.11
-2,334.23
-226
-185.41
Operating Margin (%)
14
13
14
18
19
18
16
16
Depreciation Expense
-158
-222
-347
-417
-583
-414
-351
-855
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-7,165.17
-36,669.59
-37,129.55
-173,569.58
-93,761.41
-2,804.77
-310.18
-606.15
Profit Margin (%)
- -
44
-35
-360
236
130
253
385
Working Capital
- -
271
343
289
721
497
511
712
LT Debt
- -
-118
-244
-450
-586
-488
-500
-869
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7
8
8
LT Borrowings
501
477
678
LT Finance Leases
34
33
33
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
985
1,012
1,047
Market Capitalization
2,104
1,820
7,385

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
329
315
453
Cash, Cash Equivalents & STI
258
243
381
Accounts Receivable, Net
32
43
43
Inventories
7
1
1
Total Current Liabilities
57
62
68
Payables & Accruals
30
31
47
ST Debt
7
8
8
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
41.24%
2.34%
Free Cash Flow
- -
17.66%
-22.34%
Net Income, GAAP
- -
14.46%
-15.03%
Sales/Revenue/Turnover
- -
615.63%
668.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
6
8
15
2025
17
26
32
38
113
2026
44
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.2
-0.12
-0.08
-0.59
2025
-0.15
-0.1
-0.07
-0.06
-0.38
2026
-0.62
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Co-Diagnostics, Inc. (CODX)
Vectus Biosystems Limited (VBS.AX)
Fusion Antibodies plc (FAB.L)
89bio, Inc. (ETNB)
Anavex Life Sciences Corp. (0HFR.L)
Pardes Biosciences, Inc. (PRDS)
Business
ImmunityBio, Inc. (NASDAQ: IBRX) develops next-generation immunotherapies that bolster the natural immune system to fight cancers and infectious diseases; its platforms include antibody-cytokine fusion proteins such as the FDA-approved Anktiva (N-803/nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ; vaccine vectors encompassing DNA, RNA, and adenovirus-based technologies for personalized cancer vaccines and HPV-related therapies; and cell therapies featuring NK-92-derived natural killer cells like PD-L1 t-haNK, alongside T-cell therapies and macrophage activators that target solid tumors (pancreatic, lung, colorectal), liquid tumors, HIV, and Lynch syndrome-associated cancers. The company, founded in 2014 and headquartered in San Diego, California, with additional operations in Culver City, California, and Morrisville, North Carolina, operates as a vertically integrated, commercial-stage biotechnology firm conducting internal cGMP manufacturing and a robust clinical pipeline across multiple phases and indications in collaboration with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd. Recent developments include FDA approval of Anktiva in April 2024, an $80 million equity financing via registered direct offering with institutional investors in July 2025 to support operations and clinical trials, and a partnership with nCartes announced in November 2024 to automate clinical trial data processes.

Company News

APIChatGPT

  • gurufocus.com

    ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

  • businesswire.com

    ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

  • zacks.com

    IBRX and the BCG Shortage: Deals That Could Expand Demand

  • zacks.com

    ImmunityBio: Anktiva Explained and What Comes Next

  • zacks.com

    IBRX Stock Outlook After Q1 Results and a New FDA Review

  • prnewswire.com

    The $13 Million Company Teaching the Immune System to Hunt Cancer

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

  • businesswire.com

    ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

  • globenewswire.com

    DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

  • globenewswire.com

    Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors

  • prnewswire.com

    The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

  • businesswire.com

    IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

  • gurufocus.com

    IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman

  • prnewswire.com

    IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman

  • globenewswire.com

    IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

  • newsfilecorp.com

    IBRX DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

  • globenewswire.com

    IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • globenewswire.com

    IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm